---
title: "Table-Acute Treatment for Gout"
slug: "table-acute-treatment-for-gout"
date: "2023-08-05"
enableToc: false
tags:
  - building
---

> [!info]
>
> ðŸŒ± ä¾†è‡ª: [[gout]]

# Table-Acute Treatment for Gout

| Drug                                            | Initial Dose                                               |
| ----------------------------------------------- | ---------------------------------------------------------- |
| NSAIDs (nonsel or COX-2 inhib)                  | Full anti-inflammatory dose â†’ tapering                     |
| Colchicine (PO; IV no longer available in U.S.) | 1.2 mg then â†’ 0.6 mg 1 h later â†’ 0.6 mg bid                |
| Corticosteroids (PO, IA, IV, IM)                | eg, prednisone 0.5 mg/kg/d Ã— 5-10 d Â± taper                |
| ACTH (IM)                                       | eg, 100 IU IM Ã—1-2 doses                                   |
| IL-1 inhibitors                                 | anakinra (100 mg SC qd Ã— 3 d); canakinumab (150 mg SC Ã— 1) |

Apologies for that. Here are the first and third columns:

| Drug                                            | Comments                                                                                                      |
| ----------------------------------------------- | ------------------------------------------------------------------------------------------------------------- |
| NSAIDs (nonsel or COX-2 inhib)                  | Gastritis & GIB risk. Avoid in CKD & CVD. â‰ˆ efficacy among NSAIDs.                                            |
| Colchicine (PO; IV no longer available in U.S.) | N/V/diarrhea (w/ â†‘ dose), marrow suppression, myopathy, neuropathy. â†“ dose in CKD (however, not nephrotoxic). |
| Corticosteroids (PO, IA, IV, IM)                | Rule out joint infection 1st. Corticosteroid injection if <3 joints.                                          |
| ACTH (IM)                                       | â†‘ cost, â†“ s/e, limited data (Semin Arthritis Rheum 2014;43:648)                                               |
| IL-1 inhibitors                                 | â†‘â†‘ cost; anakinra a/w injection site pain                                                                     |

- IL-1 inhibitors: Canakinumab approved in EU (Ann Rheum Dis 2012;71:1839; Arth Rheum 2010;62:3064)
